Logical Therapeutics receives seed funding from PA Early State Partners

By Lisa Kerner

Charlotte, N.C., Aug. 10 - Logical Therapeutics, Inc. said it has completed a seed round of financing in partnership with PA Early Stage Partners.

Financial details were not disclosed.

"The initial funding and our investors at PA Early Stage provide the resources we need to initiate operations, secure certain intellectual property rights and begin to execute on our clinical development strategy," executive vice president and chief operating officer Carolyn E. Green said in a company news release.

Logical Therapeutics, a privately held biotechnology company in Pittsburgh, is developing drugs to treat various forms of arthritis, obesity and type 2 diabetes mellitus.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.